Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
90
PEN Quote, Financials, Valuation and Earnings
Last price:
$350.51
Seasonality move
:
7.09%
Day range:
$345.20 - $352.15
52-week range:
$221.26 - $352.15
Dividend yield:
0%
P/E ratio:
83.76x
P/S ratio:
10.30x
P/B ratio:
10.10x
Volume:
9.7M
Avg. volume:
841.9K
1-year change:
33.89%
Market cap:
$13.7B
Revenue:
$1.2B
EPS (TTM):
$4.18
Analysts' Opinion
-
Consensus RatingPenumbra, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $339.19, Penumbra, Inc. has an estimated downside of -3.38% from its current price of $350.49.
-
Price Target UpsideAccording to analysts, the highest upside price target is $388.00 representing 10.7% upside increase from its current price of $350.49.
Fair Value
-
According to the consensus of 13 analysts, Penumbra, Inc. has -3.38% downside to fair value with a price target of $339.19 per share.
PEN vs. S&P 500
-
Over the past 5 trading days, Penumbra, Inc. has overperformed the S&P 500 by 11.71% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Penumbra, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Penumbra, Inc. has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Penumbra, Inc. reported revenues of $354.7M.
Earnings Growth
-
Penumbra, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Penumbra, Inc. reported earnings per share of $1.17.
Enterprise value:
13.5B
EV / Invested capital:
--
Price / LTM sales:
10.30x
EV / EBIT:
77.97x
EV / Revenue:
10.10x
PEG ratio (5yr expected):
0.22x
EV / Free cash flow:
88.28x
Price / Operating cash flow:
89.99x
Enterprise value / EBITDA:
69.54x
Gross Profit (TTM):
$888.3M
Return On Assets:
10.22%
Net Income Margin (TTM):
12.3%
Return On Equity:
13.4%
Return On Invested Capital:
11.35%
Operating Margin:
13.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $995.1M | $1.2B | $1.3B | $301M | $354.7M | |
| Gross Profit | $624.1M | $723.7M | $888.3M | $200.2M | $238M | |
| Operating Income | $61.6M | $78.5M | $172.8M | $35.4M | $48.8M | |
| EBITDA | $88.2M | $108.2M | $193.7M | $39.5M | $51.3M | |
| Diluted EPS | $1.04 | $0.86 | $4.18 | $0.75 | $1.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $668M | $723.6M | $868.5M | $891.8M | $1.1B | |
| Total Assets | $973.2M | $1.3B | $1.5B | $1.5B | $1.7B | |
| Current Liabilities | $116.1M | $138.3M | $145.1M | $153.2M | $169.6M | |
| Total Liabilities | $288.6M | $347.8M | $364.2M | $374.8M | $385.7M | |
| Total Equity | $684.6M | $973.8M | $1.1B | $1.1B | $1.4B | |
| Total Debt | $166.6M | $208.1M | $218M | $214.6M | $204M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $62.4M | $153.6M | $203.3M | $56.5M | $58.3M | |
| Cash From Investing | -$31.7M | $112.9M | -$189.9M | $35.7M | -$162.9M | |
| Cash From Financing | $16M | -$87.2M | $27.5M | -$100.6M | $4M | |
| Free Cash Flow | $47.3M | $134.2M | $152.6M | $51M | $42M | |
PEN
Sector
Market Cap
$13.7B
$26.5M
Price % of 52-Week High
99.53%
51.45%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.63%
1-Year Price Total Return
33.89%
-16.54%
Beta (5-Year)
0.714
0.489
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$319.43
200-day SMA
Buy
Level
$269.38
Bollinger Bands (100)
Buy
Level
250.29 - 304.85
Chaikin Money Flow
Buy
Level
46.3M
20-day SMA
Buy
Level
$316.50
Relative Strength Index (RSI14)
Buy
Level
70.58
ADX Line
Buy
Level
24.63
Williams %R
Sell
Level
-2.671
50-day SMA
Buy
Level
$297.82
MACD (12, 26)
Buy
Level
7.30
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
36.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.9879)
Buy
CA Score
(Annual)
Level (1.2569)
Buy
Beneish M-Score
(Annual)
Level (-3.103)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.8763)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
Stock Forecast FAQ
In the current month, PEN has received 8 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PEN average analyst price target in the past 3 months is $339.19.
-
Where Will Penumbra, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Penumbra, Inc. share price will drop to $339.19 per share over the next 12 months.
-
What Do Analysts Say About Penumbra, Inc.?
Analysts are divided on their view about Penumbra, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Penumbra, Inc. is a Sell and believe this share price will rise from its current level to $186.00.
-
What Is Penumbra, Inc.'s Price Target?
The price target for Penumbra, Inc. over the next 1-year time period is forecast to be $339.19 according to 13 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is PEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Penumbra, Inc. is a Buy. 8 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PEN?
You can purchase shares of Penumbra, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Penumbra, Inc. shares.
-
What Is The Penumbra, Inc. Share Price Today?
Penumbra, Inc. was last trading at $350.51 per share. This represents the most recent stock quote for Penumbra, Inc.. Yesterday, Penumbra, Inc. closed at $350.49 per share.
-
How To Buy Penumbra, Inc. Stock Online?
In order to purchase Penumbra, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PEN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PEN
Sector
P/E ratio
83.76x
23.92x
PEG ratio
0.22x
-0.01x
P/B ratio
10.10x
1.81x
Price / LTM sales
10.30x
1.60x
Growth Metrics
PEN
Sector
Revenue growth
17.82%
4.35%
Earnings growth
54.78%
9.8%
Revenue (5-year growth)
16.89%
6.41%
Earnings forecast
$1.10
-$0.18
Profitability
PEN
Sector
Profitability FY 2024
$749.8M
$3.3M
Return on invested capital
11.35%
-32.69%
Return on assets
10.22%
-29.29%
Return on equity
13.4%
-38.5%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Feb
4
Balance Sheet
PEN
Sector
Total cash
$470.3M
$25.6M
Short term investments
$15.7M
$25.1M
Total assets
$1.5B
$75.5M
Long term debt
$204M
$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
80
BNR alert for Jan 16
Burning Rock Biotech Ltd. [BNR] is up 18.69% over the past day.
Sell
44
RGC alert for Jan 16
Regencell Bioscience Holdings Ltd. [RGC] is down 14.64% over the past day.
Buy
90
PEN alert for Jan 16
Penumbra, Inc. [PEN] is up 11.83% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
